1. Current controversies in the management of metastatic colorectal cancer

   • Ruth Vera
   • Vicente Alonso
   • Manuel Valladares-Ayerbes

   Review Article 26 June 2015 Pages: 659 - 677

2. Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

   • Francesca De Iuliis
   • Gerardo Salerno
   • Susanna Scarpa

   Review Article 22 July 2015 Pages: 679 - 690

3. Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight

   • Whitney M. Bray
   • Cory Bivona
   • Tara L. Lin

   Original Article 01 August 2015 Pages: 691 - 697

   

4. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration

   • Nianhang Chen
   • Carrie Brachmann
   • Rajesh Chopra

   Original Article Open access 01 August 2015 Pages: 699 - 712

   

5. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug–drug interaction

   • Masanori Motonaga
   • Noboru Yamamoto
   • Yoshikazu Hayashi

   Original Article 02 August 2015 Pages: 713 - 721

   

6. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours

   • Ruth Plummer
   • Helen Swaisland
   • L. Rhoda Molife

   Original Article 05 August 2015 Pages: 723 - 729

   

7. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

   • G. Quintero-Aldana
   • M. Jorge
   • B. Campos Balea

   Original Article 05 August 2015 Pages: 731 - 737

   

8. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer

   • Hirofumi Mukai
   • Norikazu Masuda
   • Yuichi Ando

   Original Article 08 August 2015 Pages: 739 - 750

   

9. Absorption, distribution, metabolism, and excretion of [¹⁴C]BYL719 (alpelisib) in healthy male volunteers

   • Alexander James
   • Lars Blumenstein
   • Piet Swart

   Original Article 08 August 2015 Pages: 751 - 760

   

10. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations

    • Tomohito Kuwako
    • Hisao Imai
    • Masanobu Yamada

    Original Article 08 August 2015 Pages: 761 - 769

    

11. Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents

    • Takehito Shukuya
    • Ryo Ko
    • Kazuhisa Takahashi

    Original Article 11 August 2015 Pages: 771 - 776

    

12. A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer

    • Robin L. Jones
    • Johanna C. Bendell
    • Kathleen N. Moore

    Original Article 18 August 2015 Pages: 777 - 784

    

13. A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

    • B. Venugopal
    • A. Awada
    • S. Aamdal

    Original Article 20 August 2015 Pages: 785 - 792

14. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer

    • Ken-ichi Fujita
    • Etsuko Yoshino
    • Yasutsuna Sasaki

    Original Article 22 August 2015 Pages: 793 - 801

    

15. Oral and intravenous pharmacokinetics of 5-fluoro-2′-deoxycytidine and THU in cynomolgus monkeys and humans

    • Julianne L. Holleran
    • Jan H. Beumer
    • Julie L. Eiseman

    Original Article 01 September 2015 Pages: 803 - 811

    

16. Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib

    • John F. Deeken
    • Jan H. Beumer
    • Michelle A. Rudek

    Original Article 02 September 2015 Pages: 813 - 819

    

17. PLGA nanoparticle formulation of RK-33: an RNA helicase inhibitor against DDX3

    • Guus Martinus Bol
    • Raheela Khan
    • Venu Raman

    Original Article 02 September 2015 Pages: 821 - 827

    

18. Cetuximab plus pemetrexed as second-line therapy for fluorouracil-based pre-treated metastatic esophageal squamous cell carcinoma

    • Jing Tian
    • Ming Shang
    • Jun Xu

    Original Article 02 September 2015 Pages: 829 - 834

    

19. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer

    • Kyoko Otsuka
    • Akito Hata
    • Nobuyuki Katakami

    Original Article 08 September 2015 Pages: 835 - 841

    

20. A phase I study of volasertib combined with afatinib, in advanced solid tumors

    • Jean-Pascal Machiels
    • Marc Peeters
    • Sylvie Rottey

    Original Article 08 September 2015 Pages: 843 - 851

21. Overcoming ABCG2-mediated drug resistance with imidazo-[1,2-b]-pyridazine-based Pim1 kinase inhibitors

    • Richard A. J. Darby
    • Amanda Unsworth
    • Richard Callaghan

    Original Article 09 September 2015 Pages: 853 - 864

    

22. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial

    • Nicolas Simon
    • Olivier Romano
    • Pascal Odou

    Clinical Trial Report 21 July 2015 Pages: 865 - 871

    

23. Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study

    • Luo Fang
    • Xiaojiang Sun
    • Nengming Lin

    Short Communication 27 August 2015 Pages: 873 - 877